{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:25:52Z","timestamp":1773260752387,"version":"3.50.1"},"reference-count":92,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>The gene<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Adult patients with SAMS (on low doses of atorvastatin and simvastatin)-induced myalgia\/myopathy (n=278), patients on statins but without SAMS (n=293) and population (part of the post-MONICA [Multinational MONItoring of trends and determinants in CArdiovascular disease] study) controls (n=561) were genotyped (polymerase chain reaction-restriction fragment length polymorphism [PCR-RFLP] assay) for rs6535454 and rs4693075 polymorphisms within the<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Distribution of rs6535454 in patients with SAMS (GG=51.1%, GA=40.0%, AA=8.9%) did not significantly differ (p=0.33; respectively 0.32 for codominant models of the analysis) from that in the population controls (GG=48.1%, GA=45.0%, AA=6.9%) or the SAMS-unaffected patients (GG=49.8%, GA=40.3%, AA=9.7%). Similarly, neither rs4693075 was associated with SAMS (CC=36.8%, CG=48.2%, GG=15.0% in patients suffering SAMS vs. CC=36.6%, CG=47.5%, GG=15.9 in controls and CC=35.8%, CG=48.2%, GG=15.9% in symptom-free patients, p=0.94 and 0.95 for codominant models of the analysis). Also, the haplotype distributions were not significantly different between the groups analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The polymorphisms of the<\/jats:p><\/jats:sec>","DOI":"10.1515\/dmpt-2017-0027","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T22:47:19Z","timestamp":1513723639000},"source":"Crossref","is-referenced-by-count":3,"title":["COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia\/myopathy in the Czech population"],"prefix":"10.1515","volume":"32","author":[{"given":"Jaroslav A.","family":"Hubacek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Adamkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Zlatohlavek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Steiner-Mrazova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref581","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","article-title":"The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort","volume":"5","year":"2011","journal-title":"J Clin Lipidol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"e114283","DOI":"10.1371\/journal.pone.0114283","article-title":"Health factors and risk of all-cause, cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE studies in Lithuania","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MOL.0000000000000125","article-title":"Pharmacogenomics of statin therapy: any new insights in efficacy or safety?","volume":"25","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force","volume":"316","year":"2016","journal-title":"J Am Med Assoc"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.atherosclerosis.2010.04.007","article-title":"Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007\/8. Czech MONICA and Czech post-MONICA","volume":"211","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for DNA extraction from human nucleated cells","volume":"16","year":"1988","journal-title":"Nucleic Acid Res"},{"key":"ref901","first-page":"47","article-title":"Progress in pharmacogenetics: consortiums and new strategies","volume":"31","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/dmpt-2015-0032","article-title":"Humen genetics: international projects and personalised medicine","volume":"31","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.13207","article-title":"Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)","volume":"83","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref691","first-page":"645","article-title":"Molecular mechanisms of statin intolerance","volume":"12","year":"2016","journal-title":"Arch Med Sci"},{"key":"ref191","first-page":"609","article-title":"Impact of variants within seven candidate genes on statin treatment efficacy","volume":"61","year":"2012","journal-title":"Physiol Res"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejim.2015.02.019","article-title":"Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia\/myopathy in the Czech population","volume":"26","year":"2015","journal-title":"Eur J Intern Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01745510","article-title":"Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors","volume":"66","year":"1988","journal-title":"Klin Wochenschr"},{"key":"ref441","first-page":"47","article-title":"Progress in pharmacogenetics: consortiums and new strategies","volume":"31","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","year":"2007","journal-title":"Lipids Health Dis"},{"key":"ref31","first-page":"S121","article-title":"Traditional risk factors of acute coronary syndrome in four different male populations \u2013 total cholesterol value does not seem to be relevant risk factor","volume":"66","year":"2017","journal-title":"Physiol Res"},{"key":"ref651","first-page":"609","article-title":"Impact of variants within seven candidate genes on statin treatment efficacy","volume":"61","year":"2012","journal-title":"Physiol Res"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","year":"2012","journal-title":"Am J Cardiol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.endonu.2016.01.001","article-title":"Statin-related myotoxicity","volume":"63","year":"2016","journal-title":"Endocrinol Nutr"},{"key":"ref231","first-page":"645","article-title":"Molecular mechanisms of statin intolerance","volume":"12","year":"2016","journal-title":"Arch Med Sci"},{"key":"ref21","first-page":"58","article-title":"High cholesterol is not associated with increased mortality","volume":"3","year":"2015","journal-title":"[Article in Czech] Hyper Kardiovask Prevence"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/dmdi-2014-0021","article-title":"No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid lowering response to statin in Greek patients with primary hypercholesterolemia","volume":"30","year":"2015","journal-title":"Drug Metab Pers Ther"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","article-title":"The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort","volume":"5","year":"2011","journal-title":"J Clin Lipidol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin induced myalgia assessed by physiogenomic associations","volume":"218","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.12659\/MSM.893007","article-title":"SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia\/myopathy in a Czech population","volume":"21","year":"2015","journal-title":"Med Sci Monit"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2478\/v10136-012-0001-3","article-title":"Variant within CELSR2\/PSRC1\/SORT1, but not within CILP2\/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy","volume":"10","year":"2012","journal-title":"J Appl Biomed"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MOL.0000000000000125","article-title":"Pharmacogenomics of statin therapy: any new insights in efficacy or safety?","volume":"25","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/pgs-2016-0071","article-title":"Rare variants in known and novel candidate genes predisposing to statin-associated myopathy","volume":"17","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref541","first-page":"S327","article-title":"Statin-associated myopathy: from genetic predisposition to clinical management","volume":"63","year":"2014","journal-title":"Physiol Res"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2796.2010.02333.x","article-title":"Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up","volume":"270","year":"2011","journal-title":"J Intern Med"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.endonu.2016.01.001","article-title":"Statin-related myotoxicity","volume":"63","year":"2016","journal-title":"Endocrinol Nutr"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref201","first-page":"1","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","year":"2015","journal-title":"Arch Med Sci"},{"key":"ref111","first-page":"1","article-title":"SLCO1B1 polymorphisms and statin-induced myopathy","volume":"5","year":"2013","journal-title":"PLoS Curr"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin induced myalgia assessed by physiogenomic associations","volume":"218","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study","volume":"211","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/pgs-2016-0071","article-title":"Rare variants in known and novel candidate genes predisposing to statin-associated myopathy","volume":"17","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejim.2015.02.019","article-title":"Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia\/myopathy in the Czech population","volume":"26","year":"2015","journal-title":"Eur J Intern Med"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref361","first-page":"98","article-title":"The effect of coenzyme Q10 in statin myopathy","volume":"33","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.13207","article-title":"Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)","volume":"83","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","year":"2007","journal-title":"Lipids Health Dis"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study","volume":"211","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","year":"2006","journal-title":"J Pathol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01745510","article-title":"Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors","volume":"66","year":"1988","journal-title":"Klin Wochenschr"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for DNA extraction from human nucleated cells","volume":"16","year":"1988","journal-title":"Nucleic Acid Res"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/dmpt-2015-0032","article-title":"Humen genetics: international projects and personalised medicine","volume":"31","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"e114283","DOI":"10.1371\/journal.pone.0114283","article-title":"Health factors and risk of all-cause, cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE studies in Lithuania","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2003.09.008","article-title":"Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects","volume":"93","year":"2004","journal-title":"Am J Cardiol"},{"key":"ref571","first-page":"1","article-title":"SLCO1B1 polymorphisms and statin-induced myopathy","volume":"5","year":"2013","journal-title":"PLoS Curr"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1515\/dmpt-2015-0031","article-title":"Clinical implementation of pharmacogenetics","volume":"31","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin induced side effects","volume":"54","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1365-2753.2012.01863.x","article-title":"Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study","volume":"18","year":"2012","journal-title":"J Eval Clin Pract"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.12659\/MSM.893007","article-title":"SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia\/myopathy in a Czech population","volume":"21","year":"2015","journal-title":"Med Sci Monit"},{"key":"ref81","first-page":"S327","article-title":"Statin-associated myopathy: from genetic predisposition to clinical management","volume":"63","year":"2014","journal-title":"Physiol Res"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","year":"2006","journal-title":"J Pathol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","year":"2012","journal-title":"Am J Cardiol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.atherosclerosis.2010.04.007","article-title":"Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007\/8. Czech MONICA and Czech post-MONICA","volume":"211","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force","volume":"316","year":"2016","journal-title":"J Am Med Assoc"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1365-2753.2012.01863.x","article-title":"Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study","volume":"18","year":"2012","journal-title":"J Eval Clin Pract"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2478\/v10136-012-0001-3","article-title":"Variant within CELSR2\/PSRC1\/SORT1, but not within CILP2\/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy","volume":"10","year":"2012","journal-title":"J Appl Biomed"},{"key":"ref491","first-page":"S121","article-title":"Traditional risk factors of acute coronary syndrome in four different male populations \u2013 total cholesterol value does not seem to be relevant risk factor","volume":"66","year":"2017","journal-title":"Physiol Res"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin induced side effects","volume":"54","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1515\/dmpt-2015-0031","article-title":"Clinical implementation of pharmacogenetics","volume":"31","year":"2016","journal-title":"Drug Metab Pers Ther"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"ref661","first-page":"1","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","year":"2015","journal-title":"Arch Med Sci"},{"key":"ref821","first-page":"98","article-title":"The effect of coenzyme Q10 in statin myopathy","volume":"33","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-016-0573-6","article-title":"Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?","volume":"18","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2796.2010.02333.x","article-title":"Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up","volume":"270","year":"2011","journal-title":"J Intern Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2003.09.008","article-title":"Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects","volume":"93","year":"2004","journal-title":"Am J Cardiol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-016-0573-6","article-title":"Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?","volume":"18","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/dmdi-2014-0021","article-title":"No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid lowering response to statin in Greek patients with primary hypercholesterolemia","volume":"30","year":"2015","journal-title":"Drug Metab Pers Ther"},{"key":"ref481","first-page":"58","article-title":"High cholesterol is not associated with increased mortality","volume":"3","year":"2015","journal-title":"[Article in Czech] Hyper Kardiovask Prevence"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.2017.32.issue-4\/dmpt-2017-0027\/dmpt-2017-0027.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2017-0027\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T22:20:35Z","timestamp":1719699635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2017-0027\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":92,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1515\/dmpt-2017-0027","relation":{},"ISSN":["2363-8915","2363-8907"],"issn-type":[{"value":"2363-8915","type":"electronic"},{"value":"2363-8907","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,20]]}}}